^
    Back
    Association details:
    Biomarker:MAPK4 deletion
    Cancer:Cervical Cancer
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Exp Clin Cancer Res
    Title:

    MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer

    Published date:
    07/25/2020
    Excerpt:
    Moreover, in vivo results demonstrated that MAPK4 knockout enhanced the sensitivity of cervical cancer to radiation and PARP1 inhibitors in mouse xenograft models.
    DOI:
    10.1186/s13046-020-01644-5